Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Utah Medical Products, Inc.NASDAQ: UTMD

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of $130K (cash outflow) fell 29.3% year over year, behind the +85.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 19.3% from the prior quarter. Over 3 fiscal years it compounded at -23.2% a year.

Context

  • Capital expenditures amounted to 1.0% of revenue in FY2025, up 0.4 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -29.3% toward the trailing-twelve-month pace of +85.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$130K+19.3% QoQ
Last fiscal yearDec 2025
-$371K+57.9% YoY
LTMMar 2026
-$317K+85.4% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.3%——
1 year+57.9%——
3-year CAGR-23.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(371K) USD
Year-over-year change
-57.9%

Capital Expenditures vs competitors

How UTMD compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +85.4% is the highest of 8, against a peer median of -63.3%.
  • Capital expenditures amounts to 0.8% of revenue for UTMD, versus a peer median of 1.1%.
UTMD Competitors
Capital Expenditures for UTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$14.95M USD-70.1%+248.2%2419.3%
OSUROraSure Technologies, Inc.LTM Mar 2026$4.69M USD+77.8%-96.0%4.1%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$3.3M USD-63.3%-66.6%2.3%
NYXHNyxoah S.A.LTM Mar 2026€1.32M EUR-65.8%-63.4%8.1%
STIMNeuronetics, Inc.LTM Mar 2026$779K USD-40.5%-37.4%0.5%
KRMDKORU Medical Systems, Inc.LTM Mar 2026$578.97K USD-64.0%-30.7%1.3%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$455K USD-54.0%+37.7%0.6%
UTMDUtah Medical Products, Inc.LTM Mar 2026$317K USD+85.4%-23.2%0.8%
PREPrenetics Global LimitedLTM Mar 2026$208K USD—-68.0%0.2%
PROFProfound Medical Corp.LTM Mar 2026$179.08K USD——0.9%
CHRSCoherus Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding UTMD) —-63.3%-50.4%1.1%

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income14.79M16.47M16.64M13.87M11.29M
Depreciation & Amortization7.28M7.08M6.37M2.85M3.01M
Deferred Income Tax(92K)(401K)(681K)(338K)(659K)
Stock-Based Compensation166K183K225K256K373K
Change in Working Capital(1.01M)(2.23M)(233K)(1.8M)317K
Accounts Receivables(1.13M)(525K)2.27M(781K)333K
Inventory(485K)(2.35M)(670K)587K1.2M
Accounts Payables(23K)464K(456K)(73K)211K
Other Working Capital632K188K(1.38M)(1.54M)(1.42M)
Other Non-Cash Items63K36K(33K)(4K)367K
Operating Cash Flow21.2M21.15M22.28M14.83M14.69M
Capital Expenditures(552K)(818K)(639K)(235K)(371K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(9K)027K0
Investing Cash Flow(552K)(818K)(639K)(208K)(371K)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0(2.5M)0(19.97M)(8.36M)
Dividends Paid(11.47M)(3.16M)(4.28M)(4.26M)(3.98M)
Other Financing Activities560K174K117K390K0
Financing Cash Flow(10.91M)(5.48M)(4.17M)(23.84M)(12.34M)
Effect of Forex Changes(362K)(767K)339K(677K)797K
Net Change in Cash9.38M14.08M17.82M(9.89M)2.78M
Free Cash Flow20.65M20.33M21.64M14.6M14.32M

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.